-
After A Q4 Miss, LifePoint Health Downgraded By Leerink On Free Cash Flow Concerns
Monday, March 5, 2018 - 10:40am | 389Read More...Health care services provider LifePoint Health Inc (NASDAQ: LPNT) was hit with a downgrade by Leerink Swan while still recovering from a Friday earnings miss and subsequent stock plunge. The Rating Analyst Ana Gupte downgraded LifePoint from Outperform to Market Perform and lowered the price...
-
Leerink: Bluebird Bio's Catalysts Are Priced In
Thursday, January 25, 2018 - 11:24am | 387Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) are up 360 percent over the last two years, but Leerink said the stock’s losing steam. The Rating Leerink analyst Michael Schmidt downgraded Bluebird from Outperform to Market Perform and increased the price target from $162 to $194. The Thesis...
-
Plenty Of Opportunity In AbbVie, Even After Recent Run
Monday, October 2, 2017 - 12:18pm | 345Read More...Analysts at Leerink Swann turned bullish on AbbVie Inc (NYSE: ABBV) and sees continued upside to the stock on top of the 43 percent gain since the start of 2017. The firm's Geoffrey Porges upgraded AbbVie's stock rating from Market Perform to Outperform with a new $106 price target. The bullish...
-
Teleflex On Accelerating Top-Line Growth Trajectory; Upgrading To Outperform
Friday, September 8, 2017 - 11:34am | 375Read More...Leerink Swann said in a note released on Thursday that it is increasingly confident in Teleflex Incorporated (NYSE: TFX)'s revenue growth acceleration trajectory. The firm attributed its increased confidence to the acquisition of Neotract the company announced on Sept. 5. Accordingly, the firm...
-
Globus Medical Stands On The Brink Of Inflection; Leerink Upgrades
Wednesday, April 12, 2017 - 2:47pm | 373Read More...Considering Globus Medical Inc (NYSE: GMED) on the verge of significant revenue growth acceleration, Leerink Swann upgraded the musculoskeletal medical device company to Outperform and increased its price target from $29 to $40. The firm has been anticipating the ratings change since it downgraded...
-
A Peek Into The Markets: U.S. Stock Futures Down; Jobless Claims In Focus
Thursday, October 6, 2016 - 7:54am | 550Read More...Pre-open movers U.S. stock futures traded lower in early pre-market trade. Data on initial jobless claims for the latest week will be released at 8:30 a.m. ET. Futures for the Dow Jones Industrial Average declined 17 points to 18,184.00, while the Standard & Poor’s 500...
-
Leerink Swann Downgrades Kythera Biopharmaceuticals To Market Perform
Monday, June 29, 2015 - 8:46am | 57Read More...Analysts at Leerink Swann downgraded Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) from Outperform to Market Perform. Kythera Biopharmaceuticals shares have gained 96.46 percent over the past 52 weeks, while the S&P 500 index has surged 7.17 percent in the same period. Kythera Biopharmaceutical...
-
Leerink Swann Initiates Fitbit With Outperform
Thursday, June 25, 2015 - 9:08am | 31Read More...Leerink Swann initiated coverage on Fitbit Inc (NYSE: FIT) with a Outperform rating. Fitbit shares climbed 1.97 percent to 36.70 in after-hours trading.
-
Leerink Swann Initiates Pacira Pharmaceuticals With Market Perform
Friday, June 19, 2015 - 9:53am | 67Read More...Analysts at Leerink Swann initiated coverage on Pacira Pharmaceuticals Inc (NASDAQ: PCRX) with a Market Perform rating. The target price for Pacira Pharmaceuticals is set to $86. Pacira Pharmaceuticals shares have dropped 11.28 percent over the past 52 weeks, while the S&P 500 index has surged...
-
Leerink Swann Initiates Fate Therapeutics With Outperform
Monday, June 1, 2015 - 8:26am | 64Read More...Leerink Swann initiated coverage on Fate Therapeutics Inc (NASDAQ: FATE) with a Outperform rating. The target price for Fate Therapeutics is set to $10. Fate Therapeutics shares have dropped 6.71 percent over the past 52 weeks, while the S&P 500 index has surged 9.48 percent in the same period...
-
Leerink Swann Initiates Horizon Pharma With Outperform
Friday, May 22, 2015 - 8:24am | 64Read More...Leerink Swann initiated coverage on Horizon Pharma PLC (NASDAQ: HZNP) with a Outperform rating. The target price for Horizon Pharma is set to $37. Horizon Pharma shares have gained 126.97 percent over the past 52 weeks, while the S&P 500 index has surged 12.12 percent in the same period....
-
Leerink Swann Initiates Paratek Pharmaceuticals With Outperform
Friday, May 15, 2015 - 9:58am | 61Read More...Leerink Swann initiated coverage on Paratek Pharmaceuticals Inc (NASDAQ: PRTK) with a Outperform rating. The target price for Paratek Pharmaceuticals is set to $43. Paratek Pharmaceuticals shares have dropped 25.03 percent over the past 52 weeks, while the S&P 500 index has surged 12.95 percent...
-
Leerink Swann Initiates Carbylan Therapeutics With Outperform
Monday, May 4, 2015 - 8:59am | 44Read More...Analysts at Leerink Swann initiated coverage on Carbylan Therapeutics Inc (NASDAQ: CBYL) with a Outperform rating. The target price for Carbylan Therapeutics is set to $16. Carbylan Therapeutics' shares rose 9.04 percent to $5.91 in pre-market trading.
-
Leerink Swann Initiates Trillium Therapeutics At Outperform
Monday, April 27, 2015 - 9:18am | 64Read More...Analysts at Leerink Swann initiated coverage on Trillium Therapeutics Inc (NASDAQ: TRIL) with a Outperform rating. The target price for Trillium Therapeutics is set to $29. Trillium Therapeutics shares have gained 132.57 percent over the past 52 weeks, while the S&P 500 index has surged 13.28...
-
Leerink Swann Initiates Team Health Holdings At Outperform
Monday, April 20, 2015 - 8:45am | 71Read More...Analysts at Leerink Swann initiated coverage on Team Health Holdings LLC (NYSE: TMH) with a Outperform rating. The target price for Team Health Holdings is set to $73. Team Health Holdings shares have jumped 38.98 percent over the past 52 weeks, while the S&P 500 index has gained 11.18...
